INFORMATION DISCLOSURE STATEMENT U.S. Appln. No. 09/446,276

п				1 1					
- 1	، الما	AUD		ABSTRACT"Pharmacokinetics and bioavailability of papaverine HCI after intravenous, intracorporeal and					
	701			penis topical administration in beagle dogs." Methods Find Exp Clin Pharmacol 1992 Jun; 14(5): 373-8					
ŀ		1							
				ABSTRACT"Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits." Biol					
			, ,	Pharm Bull 1993 Mar; 16(3): 263-7					
			1 t	ABSTRACT"Studies on the nasal absorption of gentamycin." Chung Hua Erh Pi Yen Hou Ko Tsa Chih					
			,	1994; 29(3): 134-6					
			-	ABSTRACT"Pharmacokinetics and endometrial effects of vaginal administration of micronized					
	E			progesterone in an oil-based solution to postmenopausal women." Fertil Steril 1996 Apr; 65(4): 860-2					
	O L			ABSTRACT"Colonic mucus, smoking and ulcerative colitis." Ann R Coll Surg Engl 1996 Mar; 78(2): 85-91					
Λ	\ <u>'</u>	<u> </u>	_ •	ABSTRACT Colonic indexs, shoking and discretive contis. And R contour English Providers, 1000-1000					
/d)	لانا	· 설 ·	ABSTRACT"Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina					
1		ي مم		pectoris patients with dry mouth. A multicenter trial." Arzneimittelforschung 1997 Feb; 47(2): 128-31					
i	- MAR 1 9 T	WI X	1						
۱I	1000	/ 🗵	<i>≨</i> }	ABSTRACT"Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for					
N	~ \$			treatment of breakthrough pain in cancer patients." J Natl Cancer Inst 1998 Apr 15; 90(8): 611-6					
Y									
	COTEMT & T								
			// I						
H	CVAMDI	ED.	W 404	DATE CONSIDERED: 6/11/0/					
	EXAMIN	EK:	Xm	DATE CONSIDERED. 6/11/07					
	EXAMINER: Initial of citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if								
·il	-not in-con	tormar	ice-and	-not-considered. Include copy of this form with next communication.					
- 6									

					Atty. Docket No.	Serial N	o.: 09/446,2	276	
Form PTO (Rev. 2-32		9	U.S. Department of Commerce Patent & Trademark Office		، Q57234				
INF			N DISCLOSURE STATE eral sheets if necessary)	EMENT	Applicant: Yoshihisa	VISHIBE, et	al.		
					Filing Date: December 21, 1999	Group: 1615			
				U.S. PATE	NT DOCUMENTS				
Examin	05		Document Number	Date	Name	Class	Sub-	Filing Date	
Initial			Document Number	Date	Name	Ciuss	Class	(if appropriate)	
/ PE	<i>फ</i>			FOREIGN PA	TENT DOCUMENTS		<u> </u>		
$\overline{\alpha}$	0'			· · · · · · · · · · · · · · · · · · ·		Class	Sub-	Translation	
MAR 1. 9	2001	OFFICE	Document	Date	Country	Class	class	Yes/No	
XU	X	ž/	88106305	4/20/99	Japan	ļ		Yes	
			WO 92/14473	9/3/92	WIPO			Yes	
EM &	TRI		WO 97/01337	1/16/97	WIPO			Yes	
		, ,	RU 112102979	11/27/98	Russia	ļ		No	
•			11829	12/22/00	Russia			No	
			OTHER DOCUME	NTS (Including	g Author, Title, Date, Pe	rtinent Pages	, Etc.)		
$\Delta l a$	7		ABSTRACT"Nasal ab	sorption of pro	pranolol from different	dosage forms	by rats and	l dogs" J Pharm Sci	
Acc	1		1980 Dec; 69(12): 1411-						
		•	ABSTRACT"Nasal ab	sorption of test	osterone in rats" J Phari	n Sci 1984 S	ep; 73(9): 1	300-1	
		,	ABSTRACT"The time			lycerin in exc	ercise-induc	ed angina pectoris. A	
			methodological study" E						
		-	ABSTRACT"Intranasa						
		•	ABSTRACT"Compari intravenous administrati	on." Drug Des	Deliv 1986 Nov; 1(2): 1	51-6			
		Ž.	ABSTRACT"Compari Pharm Pharmacol 1986	son of bioavail	ability in man of tamox	ifen after ora	l and rectal	administration" J	
· · · <u>-</u>		•	ABSTRACT"Absolute	bioavailability	of hydromorphone after			inistration in humans:	
	 		saliva/plasma ratio and clinical effects." J Clin Pharmacol 1987 Sep; 27(9): 647-53 ABSTRACT"Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and						
				•	rug Dispos 1985 Oct-Dec; 6(4): 447-54				
		٠	ABSTRACT"Absolute saliva/plasma ration and	bioavailability	of hydromorphone afte	r peroral and	rectal adm	inistration in humans:	
	1		ABSTRACT"Pharmac	okinetics of hy	rdomorphone after intra	venous, pero	ral and rect	al administration to	
		,	human subjects." Biopha	arm Drug Dispo	os 1988 Mar-Apr; 9(2):	187-99			
	ABSTRACT"Pharmacokinetics of administration." Pharm Res 1988 No.				oioavailability of hydromorphone: effect of various routes of				
		•	ABSTRACT"Nasal ab			in the rat." J	Pharm Phar	macol 1989 Mar;	
	+		41(3): 214-5	comption of tex	aethylammanium in -ata	" Arch Int E	harmacody	n Ther 1980 Nov-Dec	
ABSTRACT"Nasal absorption of tetra 302: 7-17					aemylaninnomum m rais	s. Alchiller	narmacody	ii Thei 1909 Nov-Dee,	
		•	ABSTRACT"Pharmac guinea pig." Drugs Exp			anasal and ir	travenous a	administration in the	
		v	ABSTACT"Asthma th	erany present	trends and future prospe	cts." Compr	Ther 1990	Mar; 16(3):12-6	
		•	ABSTRACT"Transder 361-7						
	 		ABSTRACT"Intranas:	al absorption of	nhysostiamine and area	coline " I Pho	rm Sci 100	1 Aug: 80(8):750-1	
			ABSTRACT"A compa	arative evaluation	on of two transdermal n	itroglycerin c	delivery sys	tems: Nitro-Dur versus	
	1	\	Transderm-Nitro. The C	Collaborative In	vestigation Group." Cli	n Ther 1991	Sep-Oct; 13	3(5): 545-9	
ا ـ	/		ABSTRACT"Pharmac	okinetics and b	oioavailability of papave	rine HCI foll	lowing intra	venous, peroral, rectal,	
	ī	`	vaginal, topical and buce	cal administrati	on in beagle dogs." Bio	pharm Drug	Dispos 199	1 Oct; 12(7): 537-46	

¥ 13

			Atty. Docket No.	Serial N	0.	
Form PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent & Trademark Office		Q57234		09/446,276	
	RMATION DISCLOSURE STATE Use several sheets if necessary		Applicant: Yoshihisa NI	SHIBE, et al.	-	
			Filing Date: December 21, 1999	Group: 1615	_	
		U.S. PAT	ENT DOCUMENTS			
Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing Date (if appropriate)
Sect	5,147,654	9/15/92	Place et al.	424	473	
1	5,869,096	2/9/99	Barclay et al.	424	468	
T T	5,200,195	4/6/93	Dong et al.	424	473	
- 	,					
		FOREIGN P	PATENT DOCUMENTS			
	Document	Date	Country	Class	Sub- class	Translation Yes/No
						•
	OTHER DOC	UMENTS (Includin	g Author, Title, Date, Perti	nent Pages, E	c.)	
-		1				
		<u></u>	10.0			
	1				1	· · · · · · · · · · · · · · · · · · ·
EVAMINEDO	11/1 25/1/2		DATE CONSIDERED	6/11/	01	-

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MAR 3 0 2001

Form PTO-1449 (Rev. 2-32)

U.S. Department of Commerce

Atty. Docket No.

Serial No.: 09/446,276

Q57234

Confirmation No.: Unknown

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Yoshihisa NISHIBE, et al.

Filing Date:

Group:

		IIS PATI	ENT DOCUMENTS			
	D (N. 1)		Name	Class	Sub-	Filing Date
Examiner Initial	Document Number	Date	Name	Class	Class	(if appropriate)
Initial	5,733,569	3/31/98	Azria et al	424	434	6/6/95
XU	5,179,079	1/12/93	Hansen et al	514	4	11/27/91
71-01	3,173,073	1/12/73	Transcript at			
	and the second					
				-		
,		FOREIGN PA	ATENT DOCUMENTS			
- 10 5	Document	Date	Country	Class	Sub- class	Translation Yes/No
XW.	0 781 546 A1	12/27/96	EP	A61K	9/00	
Har	209 247 B					
	Augusta					
	OTHER DOCUME	ENTS (Includin	g Author, Title, Date, Pe	ertinent Page	s, Etc.)	
						
						-

EXAMINER:

not in conformance and not considered. Include copy of this form with next communication.

Initial of citation considered, whether or not citation is in conformance with MPEP 609; draw include citation if ace and not considered. Include copy of this form with next communication.